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Abstract
Background: Individual pharmacokinetic assessment is a critical component of tailored prophylaxis for hemophilia patients.
Population pharmacokinetics allows using individual sparse data, thus simplifying individual pharmacokinetic studies. Implementing
population pharmacokinetics capacity for the hemophilia community is beyond individual reach and requires a system effort.
Objective: The Web-Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS-Hemo) project aims to assemble
a database of patient pharmacokinetic data for all existing factor concentrates, develop and validate population pharmacokinetics
models, and integrate these models within a Web-based calculator for individualized pharmacokinetic estimation in patients at
participating treatment centers.
Methods: Individual pharmacokinetic studies on factor VIII and IX concentrates will be sourced from pharmaceutical companies
and independent investigators. All factor concentrate manufacturers, hemophilia treatment centers (HTCs), and independent
investigators (identified via a systematic review of the literature) having on file pharmacokinetic data and willing to contribute
full or sparse pharmacokinetic data will be eligible for participation. Multicompartmental modeling will be performed using a
mixed-model approach for derivation and Bayesian forecasting for estimation of individual sparse data. NONMEM (ICON
Development Solutions) will be used as modeling software.
Results: The WAPPS-Hemo research network has been launched and is currently joined by 30 HTCs from across the world.
We have gathered dense individual pharmacokinetic data on 878 subjects, including several replicates, on 21 different molecules
from 17 different sources. We have collected sparse individual pharmacokinetic data on 289 subjects from the participating centers
through the testing phase of the WAPPS-Hemo Web interface. We have developed prototypal population pharmacokinetics
models for 11 molecules. The WAPPS-Hemo website (available at www.wapps-hemo.org, version 2.4), with core functionalities
allowing hemophilia treaters to obtain individual pharmacokinetic estimates on sparse data points after 1 or more infusions of a
factor concentrate, was launched for use within the research network in July 2015.
Conclusions: The WAPPS-Hemo project and research network aims to make it easier to perform individual pharmacokinetic
assessments on a reduced number of plasma samples by adoption of a population pharmacokinetics approach. The project will
also gather data to substantially enhance the current knowledge about factor concentrate pharmacokinetics and sources of its
variability in target populations.
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Introduction
Hemophilia A and B are X chromosome–linked bleeding
disorders caused by mutations in the factor VIII (FVIII) and
factor IX (FIX) genes. Both factors take part in the intrinsic
pathway of blood coagulation. Affected individuals have severe,
moderate, or mild forms of the diseases, defined by factor
plasma levels of 1% or less, 2% to 5%, and 6% to 40%,
respectively. Both hemophilia A and B are rare diseases; the
prevalence of hemophilia A is 1 in 5000 male live births and
that of hemophilia B is 1 in 30,000 [1,2]. Factor replacement
therapy with plasma-derived or recombinant concentrates at
regular intervals to prevent both bleeding and the resultant joint
damage (ie, primary prophylaxis) is the mainstay of treatment
of hemophilia [2,3].
Tailoring prophylaxis to individual patient characteristics has
been suggested as an effective way to increase the net clinical
benefit of hemophilia A and B treatment [4,5]. It has been
demonstrated that hemophilia patients require either higher or
lower prophylactic doses of clotting factor replacement products
than the standard 20 to 50 IU/kg 2 to 3 times per week, and at
least one-third of the patients can be effectively treated with
lower doses or less frequent infusions [6-8]. A key element
needed to tailor prophylaxis is the estimation of the
pharmacokinetic disposition of FVIII/FIX at the individual level.
The main barriers to pharmacokinetic assessment in clinical
practice are the burden of multiple blood sampling required
over 24 to 72 hours (usually 11 points for the classical approach)
and the inconvenience for the clinician of performing the needed
calculations, which, even adopting the approximation of a single
compartment model kinetic, are beyond the expertise of most
hemophilia treaters [9]. Furthermore, most of the newer extended
half-life products require adoption of 2- or even 3- compartment
models leading to substantially more complex calculations
[10-13]. Population pharmacokinetics facilitates easier but still
reliable estimation of individual parameters using reduced data
points from each individual patient because it is based on
mathematical models derived from previous knowledge from
the entire available patient population. However, there are very
limited readily accessible comprehensive hemophilia population
pharmacokinetics applications available to clinicians. The
Web-Accessible Population Pharmacokinetic
Service—Hemophilia (WAPPS-Hemo) project aims to bridge
this gap. The original study protocol was registered at
ClinicalTrials.gov [NCT02061072].
The project has the following overarching objectives: (1) to
empower hemophilia treatment by making it easier to perform
individual pharmacokinetic assessments, (2) to allow for robust
estimation of individual pharmacokinetic parameters with a
reduced number of plasma samples, and (3) to enhance
knowledge about the pharmacokinetics of FVIII and FIX.
The project has the following specific objectives: (1) to collect
and compile published and unpublished individual classic
pharmacokinetics data (individual patient data from independent
investigators and factor concentrate manufacturers), (2) to create
and make available population pharmacokinetic models for the
concentrates derived from the data collected, (3) to develop a
Web-based application intended to use the above models to
calculate pharmacokinetic parameters for individual patients,
(4) to test system functionality by use of fabricated test data,
(5) to test the reliability of the pharmacokinetic reports provided
by WAPPS-Hemo, and (6) to determine the potential value of
this Web service for clinicians.
Methods
Study Design and Pharmacokinetics Repository
WAPPS-Hemo is a multicentric prospective project led by
McMaster University, Hamilton, Ontario, Canada. The project
is based on a population pharmacokinetics application hosted
on a Web-accessible platform developed and run by the Health
Information Research Unit, McMaster University.
Pharmaceutical companies and independent investigators will
be invited to provide already existing on-file individual
pharmacokinetic data for developing the population
pharmacokinetics models. All the factor concentrate
manufacturers having on-file pharmacokinetic data and
hemophilia treatment centers (HTCs) or independent
investigators willing to contribute full or sparse pharmacokinetic
data will be eligible for participation. All investigators of the
pharmacokinetic studies identified via a systematic review of
the literature will be contacted and invited to provide data.
Research Network
Active hemophilia treaters will be invited to participate as
coinvestigators and share ownership of the prospective
pharmacokinetic database, to which they will be invited to
provide plasma levels on sparse samples from eligible patients.
They will be invited to provide feedback on the WAPPS-Hemo
performance and functionality during the development phase
of the project and to propose any substudy they could be
interested to run in the network. Patient participation in the
project will be mediated by their participating treatment center,
as WAPPS-Hemo will not be directly available to patients.
Initial emails will be sent out to the clinicians/hemophilia treaters
to determine interest in this project. Once initial agreement of
project participation has been confirmed, research agreements
will be sent to facilitate data transfer. Research agreements will
be operationalized offline and kept on file. No remuneration
will be provided to either participating centers or patients.
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The WAPPS-Hemo project will result in the availability of a
repository of published and unpublished factor concentrate
concentration-time datasets for hemophilia patients. Published
data will be summarized in a systematic review and submitted
for publication. Further, population pharmacokinetics models
for the factor concentrates for which concentration-time data
are available will be established. The model development
process is described in a separate scientific report [14]. The
extended version of this report will be available as part of the
study documentation, while a synthetic version will be submitted
for publication. A major outcome will also be that a Web-based
WAPPS-Hemo engine will be made available to participating
clinicians that will provide tailored pharmacokinetic estimates
for their patients, including estimated terminal half-life; time
to 1%, 2%, and 5% plasma clotting factor level; and expected
plasma level of factor concentrate at 24, 48, and 72 hours
postinfusion. The engine will also report the credibility
estimates. Once the system is fully developed and validated we
will consider releasing a version of the service available to
clinicians unable or unwilling to participate in the research
network and effort. However, we envision that any users,
independent of the level of participation into the project, will
require an identification and authentication process as well as
the authorization to reuse anonymized data for modelling
purposes. Indeed, quality and reliability of the data provided to
the system and potentially used to refine the models require a
mechanism to contact the user to perform data quality checks.
Sample Size Considerations
We expect to be able to derive models for concentrates for which
we have 20 or more preexisting densely sampled individual
pharmacokinetic profiles. We expect to have data available for
4 or more different factor concentrates. We expect participation
from 10 clinical centers with each center contributing data from
approximately 10 patients.
Project Development Phases
In order to fulfill the aims and objectives, the project will be
operationalized as distinct but closely related work components
as listed below. The work components will proceed in an iterant
and parallel mode.
1. A systematic review to identify all existing publications
reporting pharmacokinetic data on FVIII and FIX
2. Collection of individual pharmacokinetic data on file from
investigators and factor concentrate manufacturers by signing
bilateral data transfer agreements
3. Establishment of population pharmacokinetics models for
factor concentrates
4. Creation of a Web-accessible platform, WAPPS-Hemo, to
calculate patient-specific pharmacokinetic estimates from
clinician-input concentration-time data
5. Integration of the population pharmacokinetics models into
the WAPPS-Hemo Web service
6. Recruitment of HTCs and hemophilia treaters from across
the world to the research network
7. User testing of the Web interface by participating centers by
use of the Software Usability Score [15] and think-aloud
techniques [16] using standardized fabricated patient data
8. Testing the reliability of the pharmacokinetic report provided
by the WAPPS-Hemo Web service
Development of the Web-Accessible Population
Pharmacokinetic Service—Hemophilia Web Interface
Overview
The system will be developed by and hosted at the Health
Information Research Unit, McMaster University, Ontario,
Canada. A cluster of fully resilient Hewlett Packard servers
(Windows Web servers in network load balancing configuration)
for hosting the site, Microsoft SQL (Microsoft Corp) for the
database, and a Windows server for the modelling software,
located in 2 different buildings, will support the system platform.
The system will incorporate fully mirrored hard disks and
redundant https connection. All WAPPS-related URLs (eg,
.com, .org, .ca) were blocked immediately at project funding
notification. All the needed licenses will be acquired, including
a single-site license for the population pharmacokinetics
software, NONMEM (ICON Development Solutions). The
website, database access interface, and back-end NONMEM
interface will be programmed in Microsoft (Microsoft Corp)
dot.Net programming language. The user interface will be device
responsive.
System Development Approach and Architecture
We will use Agile software developing methods to develop the
WAPPS-Hemo. Agile methodology was selected over the
conventional software development life cycle method because,
unlike conventional methods, it allows the team to iteratively
plan and strategize the development of the system [17]. We
indeed postulated that the Agile strategy of developing the
system in small iterations (known as sprints) is particularly
suited to a project of dynamic nature like WAPPS-Hemo
because it allows the team to adapt to changing requirements
based on short-term goal-setting stemming from a large
collaborating network of HTCs [18]. The system architecture
schema is presented in Figure 1.
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Figure 1. Schematic representation of the Web-Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS-Hemo) system architecture.
PK: pharmacokinetics; PPK: population pharmacokinetics; CTRL: control.
Figure 2. Schematic representation of the Web-Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS-Hemo) application programming
interface implementation. EMR: electronic medical record; API -application programming interface; PPK: population pharmacokinetics.
The system will be provided with an application program
interface to facilitate potential integration with electronic
medical record software, database, and clinical trial case report
forms at a later stage (see Figure 2).
Field testing will be performed by each participating center.
Initially, fabricated patient data will be used. Following
successful registration, the centers will be provided with a
standardized set of data and asked to generate records for those
patients. Population pharmacokinetics estimates will be
requested, reports generated, and feedback on the entire process
gathered; we will troubleshoot any arising issues. We will
conduct a formal usability evaluation using the Software
Usability Scale, think-aloud technique, and focus group feedback
to modify the service accordingly.
Description of Expected Information Flow on the
Website
User Registration
The home page of the website will have a section where a user
can register or log in to the service. Registration will be open
to participating centers/local investigators after they agree to
and sign the research agreement. Registration requests will be
validated before the center is activated. Data on the laboratory
tests used by the center will be collected at the time of patient
data input but will be stored as user characteristics for
subsequent use for future patients from that center.
Patient Registration
The goal is to allow the participating center to identify their
patients while still respecting privacy regulations. Patient
identification is critical in allowing re-input of the same patient's
data in the future and dispatching of the reports to the proper
requester. The patient registration module will be activated for
each participating center/investigator following ethics approval.
The system will require a local patient identifier to be created
for which any combination of alphanumeric codes will be
accepted. Identifiable personal health information will be stored
centrally, locally, or not stored at all in agreement with local
privacy and ethical requirements. Patient date of birth, sex,
diagnosis, and severity are the mandatory data required for
patient registration. Optional fields may be collected as well,
on each patient or prompted by specific characteristics (see
Figure 3). We plan to include among optional fields blood group
and inhibitors (actual and peak titer as Bethesda units/mL, date
of peak, last measurement, and actual treatment regime).
Ethnicity, race, genotype, or other information potentially
associated with pharmacokinetics will or will not be added to
the optional fields based on user feedback.
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Infusion and Plasma Level Data Entry
After a patient record is created, an infusion record can be added
(see Figure 4). This will require the input of patient body weight,
the specific factor concentrate infused, the total dose infused,
the infusion time and duration. Predose plasma factor level will
be provided when available. Postinfusion factor levels will be
input as sampling time and factor concentration in IU/mL.
Samples for which the level falls below the detection threshold
will be identified as below the level of quantitation.
Figure 3. Web-Accessible Population Pharmacokinetic Service–Hemophilia new patient entry page.
Figure 4. Web-Accessible Population Pharmacokinetic Service–Hemophilia measurement entry page.
Pharmacokinetic Estimation
After completion of the data input step, the user will request
the estimation of the individual pharmacokinetic parameters. A
congruency check will be performed on the submitted input
data. Details about the development and evaluation of the
underlying population pharmacokinetics models as well as
details of the postmodelling Bayesian estimation are provided
in a separate paper [14].
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Figure 5. Web-Accessible Population Pharmacokinetic Service–Hemophilia result page.
Reporting
Each individual infusion will be reported. The report will contain
inputted data; terminal half-life; time to 0.05, 0.02, and 0.01
IU/mL of plasma factor level with Bayesian credibility intervals;
expected plasma concentrations at 24, 48, and 72 hours; and an
interactive graphical representation of the predicted postinfusion
concentration-time profile (see Figure 5). To ensure that the
data and estimates are reliably accurate, automated and human
checks will be performed to determine congruency of the data
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and estimates before releasing the results. Therefore, there will
be no real-time reporting of the data and pharmacokinetic
estimates.
Risks
There are no additional risks to the patient beyond the risk
associated with standard of care at each participating center.
During the initial development of the service we will not offer
the Web application beyond the boundaries of the participating
centers. The website will be made available to those in the
research network during the testing phase using only fabricated
data. Although participating centers will have the opportunity
to input real patient data and receive pharmacokinetic reports,
we will clearly identify the prototypal and experimental use of
the system in both the research agreements and the website page
as a “Research service not yet ready for clinical practice.” A
clear disclaimer will indicate that “Any use of the results of the
population pharmacokinetic estimates in the care of individual
patients should not be considered part of the project in this
phase.”
Research Ethics Approval
The WAPPS-Hemo project has received ethical approval from
the Hamilton Integrated Research Ethics Board. Only data
already collected as part of other studies will be used for the
establishment of population pharmacokinetics models and, as
such, these studies have already received ethics approval. Legal
approval for the use of the data will be sought from the owner
of the data. Any other applicable procedures will also be
followed.
The local investigator from the participating center will submit
the WAPPS-Hemo study protocol, including a localized consent
form, to their local ethical review board for approval. The
coordinating center at McMaster will support the local
investigator in the application to the local research ethics board
if requested to do so. The local investigator will obtain informed
consent for the input of patient data on the WAPPS-Hemo
system from each participant whose data is provided. Copies
of the ethical approval and informed consent letters will be
stored locally. When a participating center submits patient data
to WAPPS-Hemo, the investigator will need to declare that the
patients have provided consent. Any important protocol
modifications will be sent to the relevant parties through email.
Data Access, Security, and Confidentiality
Only anonymized patient data already collected as part of
clinical studies or on file from factor concentrate manufacturers
will be collected for the development of models. No personal
identifying information such as name or social insurance number
will be collected.
In the prospective phase, users will be allowed to access and
use the system only after a moderated registration process. The
head of the participating center will be required to go through
a registration process, and following validation by the core
McMaster team, that person will receive credentials to access
the website and will subsequently be able to authorize other
users from the center to access the system. Each individual user
will have unique access credentials and will be authorized to
manage patients from the center she or he belongs to. Only
authorized users will be able to create and access patient records
and input the information required for the pharmacokinetic
assessment.
For the initial identification of patients, the system will require
a local patient identifier to be created for which any combination
of alphanumeric codes will be accepted. It will then be the
responsibility of the participating center to track the local patient
WAPPS-Hemo identifier in the patient case report form. Each
center will be free to adopt, in respect of their local ethical and
privacy regulation and by-laws, any structured or unstructured
way of identifying their patients, including the use of
alphanumeric strings for patient first and last names. Whenever
possible, use of an existing patient identifier from the local
health care system as WAPPS identifier is recommended.
All data held at McMaster will be stored on a secure server with
adequate physical, technical, and administrative safeguards.
Physical access to the data center is limited to the information
technology manager and programmers of the unit via a swipe
card system and is monitored at all times by video surveillance.
The administrative website and backup database will be
accessible only over a virtual private network. The system will
be available around the clock with expected downtime less than
0.1%. Access to the Web service will be tightly controlled via
robust passwords. We will use a secure https connection for
added security. Any data used for statistical analysis and
reporting will have been previously anonymized. Only the
research team will have access to the data.
Participants of this project will not be identified in any reports
or publications. No paper records of the data will be maintained.
Patients will have the right to request complete cancellation of
their personal data through the local investigator or to
completely deidentify any concentration-time points (this last
information will be retained in the system if already used for
scientific reporting for as long as allowed by current regulation).
Results Dissemination Policy
As a part of a research project, results from all the above
activities will be reported in peer-review publications. All
scientific communications regarding the population
pharmacokinetics models (whether abstract, scientific meeting,
or peer-reviewed publication) stemming from this project will
go through a formal approval step with all the entitled authors,
including any factor concentrate manufacturer’s publication
committee.
Project Funding and Sustainability
The development and initial operation of the WAPPS-Hemo
website is supported by a research grant, awarded as result of
a competitive peer-reviewed grant competition by the
Association of Hemophilia Center Directors of Canada Baxter
Canadian Hemophilia Epidemiological Research Program. We
plan to seek additional research funding and to sustain ongoing
operation of the project with intramural funds from the Health
Information Research Unit of McMaster University.
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The WAPPS-Hemo research network currently involves 47
registered active HTCs from across the world. Figure 6
illustrates the geographical distribution of the network.
An additional 26 HTCs are in various stages of the internal
approval process, and 29 more HTCs have expressed interest
in joining the network.
We have collected dense individual pharmacokinetic data on
878 subjects, including several replicates, on 21 different
molecules from 17 different sources. We have collected sparse
individual pharmacokinetic data on 289 subjects from the
participating centers through the testing phase of the
WAPPS-Hemo Web interface.
We have developed prototypal population pharmacokinetics
models for 11 molecules. All developed models and
methodological issues involved in the development and
validation of models are reported in separate scientific reports
[14,19]. In brief, assessment of validity of a system like
WAPPS-Hemo is a complex process which will be covered in
a stepwise fashion. After validation of the population models
by bootstrapping and comparing population and structural
estimates, we will prospectively validate the prediction by asking
WAPPS-Hemo users to resample the patient after the
pharmacokinetics has been estimated; the measurements will
be used to assess the goodness (validity, precision) of the
prediction. The final validation step will be to assess the impact
of adopting WAPPS-Hemo–based forecasts to tailor treatment.
This will require an ad hoc designed prospective clinical trial,
currently in the planning stage.
The WAPPS-Hemo website (available at www.wapps-hemo.org,
version 2.40), with core functionalities allowing hemophilia
treaters to obtain individual pharmacokinetic estimates on sparse
data points after 1 or more infusions of a factor concentrate,
was launched for use within the research network. Asynchronous
user support is currently made available via a monitored email
service; we expect response time within the following working
day, and a phone interaction can be started by the help desk
when deemed to be necessary.
A formal usability study of the WAPPS-Hemo interface
involving 13 participants (physicians, nurses, and clinical
coordinators) from 2 centers in Canada, 1 in the United States,
1 in the United Kingdom, and 1 in Turkey has been performed.
Two iterations resulted in new releases of the software interface.
Detailed results will be reported in a separate publication. The
WAPPS-Hemo interface has been translated into 11 languages:
Arabic, Chinese, English, French, German, Italian, Japanese,
Farsi, Portuguese, Spanish, and Turkish.
Two large prospective studies addressing the value of
pharmacokinetic tailored prophylaxis, one in hemophilia A and
one in hemophilia B, have been recently funded and are
underway in the United States, both adopting WAPPS-Hemo
as the population pharmacokinetics engine (personal
communication).
Figure 6. Web-Accessible Population Pharmacokinetic Service–Hemophilia research network.
Discussion
Overview
The WAPPS-Hemo service is the first dedicated population
pharmacokinetics calculator available on an institutional website,
essentially simplifying and facilitating individual
pharmacokinetic assessment for treatment of hemophilia A and
B. We expect that the widespread adoption of the system will
lead to a reduction in the need for blood samples in individual
patients, with particular benefit for the assessment of
pharmacokinetics in pediatric patients. The capability of
assessing pharmacokinetic parameters on sparse data will bear
the potential to extend the use of pharmacokinetics to different
scopes, including monitoring and optimizing prophylaxis
regimes, identifying individual treatment targets, and switching
from product to product. This should result in better care while
optimizing resource utilization.
The WAPPS-Hemo system is built for progressive refinement
of its own capabilities. Patient data will be periodically merged
into the reference database of the system, and models will be
JMIR Res Protoc 2016 | vol. 5 | iss. 4 | e239 | p.8http://www.researchprotocols.org/2016/4/e239/
(page number not for citation purposes)
Iorio et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
periodically recalibrated. This continuous quality assurance
process will enhance its capability to perform precise
predictions.
The WAPPS-Hemo system is built to support research and
knowledge translation. The system will progressively accrue
individual pharmacokinetic data for both hemophilia A and B
and different factor concentrates, which will be shared within
the WAPPS-Hemo research network. The availability of a large
database of pharmacokinetic data jointly with a research network
of centers with a specific interest in pharmacokinetics will pave
the way to a deeper understanding of the individual
pharmacokinetic properties of different concentrates and will
increase the evidence base used to treat hemophilia patients.
Limitations
The main limitation of the current project design is the need for
users to have some basic understanding of pharmacokinetics.
Indeed, the system does not have built-in functions to support
simulation of different dose regimens. Other limitations are
integral to the need to demonstrate the true net impact of
population pharmacokinetics modelling in hemophilia care, the
identification of the most efficient sparse sampling protocols,
and the identification of relevant covariates to maximize the
impact of using a population pharmacokinetics approach.
Conclusion
In summary, WAPPS-Hemo is well positioned and has become
the largest pharmacokinetic data repository in the field. The
interconnection of a Bayesian engine, population
pharmacokinetic routines, and smart end-user interface constitute
an innovative blend of different high-tech approaches with
potential to impact the care of hemophilia.
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